Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study

Alexandre Louvet, Julien Labreuche, Florent Artru, Alexis Bouthors, Benjamin Rolland, Pierre Saffers, Julien Lollivier, Elise Lemaître, Sébastien Dharancy, Guillaume Lassailly, Valérie Canva‐Delcambre, Alain Duhamel, Philippe Mathurin – 29 April 2017 – Understanding the mechanisms of outcome according to the time frame can help optimize the therapeutic development in severe alcoholic hepatitis.

Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study

Alexandre Louvet, Julien Labreuche, Florent Artru, Alexis Bouthors, Benjamin Rolland, Pierre Saffers, Julien Lollivier, Elise Lemaître, Sébastien Dharancy, Guillaume Lassailly, Valérie Canva‐Delcambre, Alain Duhamel, Philippe Mathurin – 29 April 2017 – Understanding the mechanisms of outcome according to the time frame can help optimize the therapeutic development in severe alcoholic hepatitis.

Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice

Yingjie Bian, Zheng Zhang, Zhichen Sun, Juanjuan Zhao, Danming Zhu, Yang Wang, Sherry Fu, Jingya Guo, Longchao Liu, Lishan Su, Fu‐Sheng Wang, Yang‐Xin Fu, Hua Peng – 26 April 2017 – Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen.

Polo‐like‐kinase 1 is a proviral host factor for hepatitis B virus replication

Ahmed Diab, Adrien Foca, Floriane Fusil, Thomas Lahlali, Pascal Jalaguier, Fouzia Amirache, Lia N'Guyen, Nathalie Isorce, François‐Loïc Cosset, Fabien Zoulim, Ourania Andrisani, David Durantel – 26 April 2017 – Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo‐like‐kinase 1 (PLK1) as a positive effector of HBV replication.

Polo‐like‐kinase 1 is a proviral host factor for hepatitis B virus replication

Ahmed Diab, Adrien Foca, Floriane Fusil, Thomas Lahlali, Pascal Jalaguier, Fouzia Amirache, Lia N'Guyen, Nathalie Isorce, François‐Loïc Cosset, Fabien Zoulim, Ourania Andrisani, David Durantel – 26 April 2017 – Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo‐like‐kinase 1 (PLK1) as a positive effector of HBV replication.

SIRT1/HSF1/HSP pathway is essential for exenatide‐alleviated, lipid‐induced hepatic endoplasmic reticulum stress

Xiaobin Zheng, Fen Xu, Hua Liang, Huanyi Cao, Mengyin Cai, Wen Xu, Jianping Weng – 25 April 2017 – Recent studies have indicated that lipid‐induced endoplasmic reticulum (ER) stress is a major contributor to the progression of hepatic steatosis. Exenatide (exendin‐4), a glucagon‐like peptide‐1 receptor agonist, is known to improve hepatic steatosis, with accumulating evidence. In this study, we investigated whether exenatide could alleviate lipid‐induced hepatic ER stress through mammal sirtuin 1 (SIRT1) and illustrated the detailed mechanisms.

Subscribe to